Showing results (131-140 of 202) with videos related to

Sort By:
Pageof 21
American Journal of Clinical Pathology|October 12, 2002
Differences in CD33 intensity between various myeloid neoplasmsIman Jilani, Elihu Estey, Yang Huh, et al.
British Journal of Haematology|May 4, 2011
Tanespimycin and bortezomib combination treatment in patients with relapsed or relapsed and refractory multiple myeloma: results of a phase 1/2 studyPaul G Richardson, Asher A Chanan-Khan, Sagar Lonial, et al.
Blood|January 25, 2002
Prognostic factors and scoring systems in chronic myelomonocytic leukemia: a retrospective analysis of 213 patientsFrancesco Onida, Hagop M Kantarjian, Terry L Smith, et al.
Blood|August 2, 2003
Transient down-modulation of CD20 by rituximab in patients with chronic lymphocytic leukemiaIman Jilani, Susan O'Brien, Taghi Manshuri, et al.
Cancer Research|April 23, 2009
Kit inhibitor APcK110 induces apoptosis and inhibits proliferation of acute myeloid leukemia cellsStefan Faderl, Ashutosh Pal, William Bornmann, et al.
Cancer|May 27, 2003
Results of imatinib mesylate therapy in patients with refractory or recurrent acute myeloid leukemia, high-risk myelodysplastic syndrome, and myeloproliferative disordersJorge Cortes, Francis Giles, Susan O'Brien, et al.
Blood|November 26, 2002
Circulating CD20 is detectable in the plasma of patients with chronic lymphocytic leukemia and is of prognostic significanceTaghi Manshouri, Kim-anh Do, Xuemei Wang, et al.
Cancer Biomarkers : Section a of Disease Markers|February 27, 2009
Detection of nucleophosmin gene mutations in plasma from patients with acute myeloid leukemia: clinical significance and implicationsWanlong Ma, Hagop Kantarjian, Xi Zhang, et al.
American Journal of Hematology|November 6, 2018
Recommendations for the assessment and management of measurable residual disease in adults with acute lymphoblastic leukemia: A consensus of North American expertsNicholas J Short, Elias Jabbour, Maher Albitar, et al.
British Journal of Haematology|January 17, 2007
The haematopoietic cell transplantation comorbidity index score is predictive of early death and survival in patients over 60 years of age receiving induction therapy for acute myeloid leukaemiaFrancis J Giles, Gautam Borthakur, Farhad Ravandi, et al.
Pageof 21